Although mTOR inhibitors (mTORi) such as everolimus and sirolimus have demonstrated their effectiveness in treating TSC-associated tumors such as subependymal giant cell astrocytoma (SEGA) and renal angiomyolipomas,18,19 there are currently no results from randomized clinical trials evaluating the efficacy of these drugs in patients with symptomatic CRs.13,16,17. The gene discussed is MTOR; the disease is tuberous sclerosis.